BACKGROUND AND PURPOSE: Helical tomotherapy (HT, Hi-Art TomoTherapy(®)) is a recently developed radiation device delivering highly conformal dose with a rotational gantry resulting in more uniform target doses and better avoidance of organs at risk. Treatment failure patterns in head and neck cancer (HNC) patients treated with HT were analyzed. PATIENTS AND METHODS: 63 patients with a biopsy-proven HNC were treated with HT. In patients with locoregional failure, the volume of failure (Vf) was contoured and co-registered with the initial planning computed tomography scan. With the use of dose-volume histogram (DVH) analysis, the Vf was classified as "in-field" (InF), "marginal" (MF) or "outside-field" (OutF), if ≥ 95%, 20-94%, and < 20% of Vf, respectively, were within the 95% isodose. RESULTS: Median follow-up time was 25 months (95% confidence interval 19.4-28 months). 2-year overall survival, disease-free survival, and locoregional control were 66%, 54%, and 77%, respectively. 13 patients developed a locoregional failure (four local, eight regional, and one local and regional). After DVH analysis, there were ten InF and two MF recurrences as well as one OutF recurrence. CONCLUSION: Target delineation and coverage were adequate. The majority of locoregional failures were InF, i.e., in the high-dose region. Future work on dose escalation to the highest risk regions is recommended.
BACKGROUND AND PURPOSE: Helical tomotherapy (HT, Hi-Art TomoTherapy(®)) is a recently developed radiation device delivering highly conformal dose with a rotational gantry resulting in more uniform target doses and better avoidance of organs at risk. Treatment failure patterns in head and neck cancer (HNC) patients treated with HT were analyzed. PATIENTS AND METHODS: 63 patients with a biopsy-proven HNC were treated with HT. In patients with locoregional failure, the volume of failure (Vf) was contoured and co-registered with the initial planning computed tomography scan. With the use of dose-volume histogram (DVH) analysis, the Vf was classified as "in-field" (InF), "marginal" (MF) or "outside-field" (OutF), if ≥ 95%, 20-94%, and < 20% of Vf, respectively, were within the 95% isodose. RESULTS: Median follow-up time was 25 months (95% confidence interval 19.4-28 months). 2-year overall survival, disease-free survival, and locoregional control were 66%, 54%, and 77%, respectively. 13 patients developed a locoregional failure (four local, eight regional, and one local and regional). After DVH analysis, there were ten InF and two MF recurrences as well as one OutF recurrence. CONCLUSION: Target delineation and coverage were adequate. The majority of locoregional failures were InF, i.e., in the high-dose region. Future work on dose escalation to the highest risk regions is recommended.
Authors: Megan E Daly; Yeeyie Lieskovsky; Todd Pawlicki; Jervis Yau; Harlan Pinto; Michael Kaplan; Willard E Fee; Albert Koong; Don R Goffinet; Lei Xing; Quynh-Thu Le Journal: Head Neck Date: 2007-03 Impact factor: 3.147
Authors: Dirk Verellen; Mark De Ridder; Nadine Linthout; Koen Tournel; Guy Soete; Guy Storme Journal: Nat Rev Cancer Date: 2007-12 Impact factor: 60.716
Authors: Min Yao; Kenneth J Dornfeld; John M Buatti; Mark Skwarchuk; Huaming Tan; Thanh Nguyen; Judith Wacha; John E Bayouth; Gerry F Funk; Russell B Smith; Scott M Graham; Kristi Chang; Henry T Hoffman Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-01 Impact factor: 7.038
Authors: Barbara Bussels; Annelies Maes; Robert Hermans; Sandra Nuyts; Caroline Weltens; Walter Van den Bogaert Journal: Radiother Oncol Date: 2004-08 Impact factor: 6.280
Authors: Vincent Grégoire; Wilfried De Neve; Avraham Eisbruch; Nancy Lee; Danielle Van den Weyngaert; Dirk Van Gestel Journal: Oncologist Date: 2007-05
Authors: K S Clifford Chao; Gokhan Ozyigit; Binh N Tran; Mustafa Cengiz; James F Dempsey; Daniel A Low Journal: Int J Radiat Oncol Biol Phys Date: 2003-02-01 Impact factor: 7.038
Authors: Dirk Rades; Nina D Seibold; Maximilian P Gebhard; Frank Noack; Steven E Schild; Christoph Thorns Journal: Strahlenther Onkol Date: 2011-09-19 Impact factor: 3.621
Authors: Christina A Wicker; Brian G Hunt; Sunil Krishnan; Kathryn Aziz; Shobha Parajuli; Sarah Palackdharry; William R Elaban; Trisha M Wise-Draper; Gordon B Mills; Susan E Waltz; Vinita Takiar Journal: Cancer Lett Date: 2021-01-12 Impact factor: 8.679
Authors: A K Due; I R Vogelius; M C Aznar; S M Bentzen; A K Berthelsen; S S Korreman; C A Kristensen; L Specht Journal: Strahlenther Onkol Date: 2012-05-13 Impact factor: 3.621
Authors: Dirk Van Gestel; Dirk Verellen; Lien Van De Voorde; Bie de Ost; Geert De Kerf; Olivier Vanderveken; Carl Van Laer; Danielle Van den Weyngaert; Jan B Vermorken; Vincent Gregoire Journal: Oncologist Date: 2013-05-30
Authors: Felix Zwicker; Falk Roeder; Christian Thieke; Carmen Timke; Marc W Münter; Peter E Huber; Jürgen Debus Journal: Strahlenther Onkol Date: 2010-12-23 Impact factor: 3.621
Authors: V E M Mul; J M A de Jong; L H P Murrer; P L A van den Ende; R M A Houben; M Lacko; P Lambin; B G Baumert Journal: Strahlenther Onkol Date: 2011-12-23 Impact factor: 3.621